Evidence map›Paper›PMID 35655220›Full record

ArticleJournal of experimental & clinical cancer research : CR2022

The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease.

Antonio Cigliano, Shanshan Zhang, Silvia Ribback, Sara Steinmann, Marcella Sini, Cindy E Ament, Kirsten Utpatel, Xinhua Song, Jingxiao Wang, Maria G Pilo and 12 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Cholangiocarcinoma 2026: status quo, unmet needs and priorities.Nature reviews. Gastroenterology & hepatology · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. HSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinoma.Journal of experimental & clinical cancer research : CR · 2024
    Article
  9. Article
  10. Review
  11. Article
  12. Complex roles of Hippo-YAP/TAZ signaling in hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2023
    Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 4 countries.

Antonio CiglianoInstitute of Pathology, University of Regensburg, Franz-Josef-Strauß-Allee 11, Regensburg, Germany.
Shanshan ZhangDepartment of Bioengineering and Therapeutic Sciences and Liver Center, University of California, 513 Parnassus Avenue, San Francisco, CA, USA.
Silvia RibbackInstitute of Pathology, University of Greifswald, Greifswald, Germany.
Sara SteinmannInstitute of Pathology, University of Regensburg, Franz-Josef-Strauß-Allee 11, Regensburg, Germany.
Marcella SiniExperimental Pathology Unit, Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.
Cindy E AmentInstitute of Pathology, University of Regensburg, Franz-Josef-Strauß-Allee 11, Regensburg, Germany.
Kirsten UtpatelInstitute of Pathology, University of Regensburg, Franz-Josef-Strauß-Allee 11, Regensburg, Germany.
Xinhua SongDepartment of Bioengineering and Therapeutic Sciences and Liver Center, University of California, 513 Parnassus Avenue, San Francisco, CA, USA.
Jingxiao WangDepartment of Bioengineering and Therapeutic Sciences and Liver Center, University of California, 513 Parnassus Avenue, San Francisco, CA, USA.
Maria G PiloInstitute of Pathology, University of Greifswald, Greifswald, Germany.
Fabian BergerInstitute of Pathology, University of Regensburg, Franz-Josef-Strauß-Allee 11, Regensburg, Germany.
Haichuan WangDepartment of Bioengineering and Therapeutic Sciences and Liver Center, University of California, 513 Parnassus Avenue, San Francisco, CA, USA.
Junyan TaoDepartment of Bioengineering and Therapeutic Sciences and Liver Center, University of California, 513 Parnassus Avenue, San Francisco, CA, USA.
Xiaolei LiDepartment of Bioengineering and Therapeutic Sciences and Liver Center, University of California, 513 Parnassus Avenue, San Francisco, CA, USA.
Giovanni M PesDepartment of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
Serena MancarellaNational Institute of Gastroenterology "S. de Bellis", Research Hospital, Castellana Grotte, Italy.
Gianluigi GiannelliNational Institute of Gastroenterology "S. de Bellis", Research Hospital, Castellana Grotte, Italy.
Frank DombrowskiInstitute of Pathology, University of Greifswald, Greifswald, Germany.
Matthias EvertInstitute of Pathology, University of Regensburg, Franz-Josef-Strauß-Allee 11, Regensburg, Germany.
Diego F CalvisiInstitute of Pathology, University of Regensburg, Franz-Josef-Strauß-Allee 11, Regensburg, Germany.
Xin ChenDepartment of Bioengineering and Therapeutic Sciences and Liver Center, University of California, 513 Parnassus Avenue, San Francisco, CA, USA.
Katja EvertInstitute of Pathology, University of Regensburg, Franz-Josef-Strauß-Allee 11, Regensburg, Germany. katja.evert@ukr.de.
University of Regensburg · DEUniversity of California, San Francisco · USUniversität Greifswald · DEGastroenterology Hospital "Saverio de Bellis" · ITUniversity of Sassari · ITCancer Center of Hawaii · USUniversity of Cagliari · IT

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
Signaling cascades in cholangiocarcinoma developmentR01CA190606 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHEN, XIN · 2016 to 2020
$1.8M
NCI NIH HHS R01 CA190606NIDDK NIH HHS P30 DK026743NIH HHS R01CA190606
6 · The paper itself

Abstract

backgroundIntrahepatic cholangiocarcinoma (iCCA) is a highly aggressive primary liver tumor with increasing incidence worldwide, dismal prognosis, and few therapeutic options. Mounting evidence underlines the role of the Hippo pathway in this disease; however, the molecular mechanisms whereby the Hippo cascade contributes to cholangiocarcinogenesis remain poorly defined.

methodsWe established novel iCCA mouse models via hydrodynamic transfection of an activated form of transcriptional coactivator with PDZ-binding motif (TAZ), a Hippo pathway downstream effector, either alone or combined with the myristoylated AKT (myr-AKT) protooncogene, in the mouse liver. Hematoxylin and eosin staining, immunohistochemistry, electron microscopy, and quantitative real-time RT-PCR were applied to characterize the models. In addition, in vitro cell line studies were conducted to address the growth-promoting roles of TAZ and its paralog YAP.

resultsOverexpression of TAZ in the mouse liver triggered iCCA development with very low incidence and long latency. In contrast, co-expression of TAZ and myr-AKT dramatically increased tumor frequency and accelerated cancer formation in mice, with 100% iCCA incidence and high tumor burden by 10 weeks post hydrodynamic injection. AKT/TAZ tumors faithfully recapitulated many of the histomolecular features of human iCCA. At the molecular level, the development of the cholangiocellular lesions depended on the binding of TAZ to TEAD transcription factors. In addition, inhibition of the Notch pathway did not hamper carcinogenesis but suppressed the cholangiocellular phenotype of AKT/TAZ tumors. Also, knockdown of YAP, the TAZ paralog, delayed cholangiocarcinogenesis in AKT/TAZ mice without affecting the tumor phenotype. Furthermore, human preinvasive and invasive iCCAs and mixed hepatocellular carcinoma/iCCA displayed widespread TAZ activation and downregulation of the mechanisms protecting TAZ from proteolysis.

conclusionsOverall, the present data underscore the crucial role of TAZ in cholangiocarcinogenesis.

Indexed as

Bile Duct NeoplasmsCarcinoma, HepatocellularCholangiocarcinomaAdaptor Proteins, Signal TransducingAnimalsBile Ducts, IntrahepaticHippo Signaling PathwayHumansMiceProtein Serine-Threonine KinasesProto-Oncogene Proteins c-aktSignal TransductionYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingProtein Serine-Threonine KinasesProto-Oncogene Proteins c-aktYAP-Signaling ProteinsAKTHippo pathwayIntrahepatic cholangiocarcinomaNotchTAZTEAD transcription factors

Identifiers

PMID35655220
PMCPMC9164528
OpenAlexW4281973560

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.